Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of “Buy” from Analysts

Insmed, Inc. (NASDAQ:INSM) has earned an average rating of “Buy” from the twenty-four brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twenty have issued a buy rating and three have assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $212.6667.

Several research analysts recently commented on the stock. Mizuho boosted their target price on Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Rothschild & Co Redburn set a $263.00 price target on Insmed in a report on Thursday, December 4th. Leerink Partners boosted their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 24th. TD Cowen set a $241.00 price objective on shares of Insmed in a report on Thursday, December 18th. Finally, UBS Group decreased their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th.

Insmed Price Performance

Shares of INSM stock opened at $164.86 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The stock has a 50 day moving average price of $150.14 and a 200 day moving average price of $166.41. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. The firm has a market capitalization of $35.54 billion, a P/E ratio of -25.72 and a beta of 1.10.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.32) EPS. As a group, sell-side analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other Insmed news, CFO Sara Bonstein sold 748 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $116,942.32. Following the sale, the chief financial officer directly owned 79,758 shares of the company’s stock, valued at approximately $12,469,365.72. This trade represents a 0.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Roger Adsett sold 791 shares of Insmed stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total value of $123,530.47. Following the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at $16,680,517.70. The trade was a 0.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 189,651 shares of company stock worth $31,533,654 in the last 90 days. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently bought and sold shares of INSM. CIBC Private Wealth Group LLC raised its position in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the period. CoreCap Advisors LLC acquired a new stake in shares of Insmed during the 4th quarter valued at about $27,000. Stone House Investment Management LLC purchased a new position in shares of Insmed in the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. increased its stake in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares in the last quarter. Finally, GraniteShares Advisors LLC acquired a new position in Insmed in the 4th quarter worth about $30,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.